Trading update
Oslo, Norway (12 June 2020) - NattoPharma continues to see a strong demand for our products during the second quarter, and we are experiencing Q2 revenue to be in the range of NOK 44-54 million resulting in a H1-2020 revenue in the range of NOK 100-110 million. This is more than 70% growth compared to H1-2019. The Adj. EBITDA margin is expected to be in excess of 15% for H1-2020, compared to the current guiding of 10-15% for the full year. The current performance builds on our confidence to deliver on the guiding for the full year as communicated during the Q1 release. During the second